Food-drug interactions: Effect of capsaicin on the pharmacokinetics of simvastatin and its active metabolite in rats

Food and Chemical Toxicology

Volumn 53, Issue , 2013, Pages 168-173

  Zhai, Xue jia ^a   Chen, Jian guo ^b   Liu, Jin mei ^a   Shi, Fang ^a   Lu, Yong ning ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Capsaicin; Cytochrome P450; Interaction; Pharmacokinetics; Rats; Simvastatin

Indexed keywords

CAPSAICIN; DRUG METABOLITE; SIMVASTATIN; SIMVASTATIN ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG TRANSFORMATION; FEMALE; FOOD DRUG INTERACTION; IN VIVO STUDY; IONIZATION; NONHUMAN; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CAPSAICIN; CAPSICUM; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP3A; DEXAMETHASONE; FEMALE; FOOD-DRUG INTERACTIONS; KETOCONAZOLE; MASS SPECTROMETRY; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN;

CAPSICUM ANNUUM VAR. ANNUUM; RATTUS;

EID: 84871667873     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.11.045     Document Type: Article

References (31)

1. An D., Yao Z.Y., He G.Y. The medium of fluorine carrier - chili in the pollution of fluoride in Guizhou. Endemic Dis. Bull. 1996, 11:55-57.
2. Babbar S., Chanda S., Bley K. Inhibition and induction of human cytochrome P450 enzymes in vitro by capsaicin. Xenobiotica 2010, 40:807-816.
3. Belza A., Frandsen E., Kondrup J. Body fat loss achieved by stimulation of thermogenesis by a combination of bioactive food ingredients: a placebo-controlled, double-blind 8-week intervention in obese subjects. Int. J. Obes. (Lond) 2007, 31:121-130.
4. Bode A.M., Dong Z. The two faces of capsaicin. Cancer Res. 2011, 71:2809-2814.
5. Buck S.H., Burks T.F. Capsaicin: hot new pharmacological tools. Trends Pharmacol. Sci. 1983, 4:84-87.
6. Chen X.W., Serag E.S., Sneed K.B., Zhou S.F. Herbal bioactivation, molecular targets and the toxicity relevance. Chem. Biol. Interact. 2011, 192:161-176.
7. Díaz-Laviada I. Effect of capsaicin on prostate cancer cells. Future Oncol. 2010, 6:1545-1550.
8. Gooding S.M., Canter P.H., Coelho H.F., Boddy K., Ernst E. Systematic review of topical capsaicin in the treatment of pruritus. Int. J. Dermatol. 2010, 49:858-865.
9. Hachiya S., Kawabata F., Ohnuki K., Inoue N., Yoneda H., Yazawa S., Fushiki T. Effects of CH-19 Sweet, a non-pungent cultivar of red pepper, on sympathetic nervous activity, body temperature, heart rate, and blood pressure in humans. Biosci. Biotechnol. Biochem. 2007, 71:671-676.
10. Hayman M., Kam P.C.A. Capsaicin: a review of its pharmacology and clinical applications. Curr. Anaesth. Crit. Care 2008, 19:338-343.
11. Hirotani Y., Yamamoto K., Tomishi H., Nishihori T., Umeda T., Tanaka K. Effects of capsaicin on the pharmacokinetics of digoxin, phenytoin, and theophylline in rats. Jpn. J. TDM 2007, 24:23-28.
12. Holtzman C.W., Wiggins B.S., Spinler S.A. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 2006, 26:1601-1607.
13. Ishigami M., Kawabata K., Takasaki W., Ikeda T., Komai T., Ito K., Sugiyama Y. Drug interaction between simvastatin and itraconazole in male and female rats. Drug Metab. Dispos. 2001, 29:1068-1072.
14. Josse A.R., Sherriffs S.S., Holwerda A.M., Andrews R., Staples A.W., Phillips S.M. Effects of capsinoid ingestion on energy expenditure and lipid oxidation at rest and during exercise. Nutr. Metab. (Lond) 2010, 3:65.
15. Lim K., Yoshioka M., Kikuzato S., Kiyonaga A., Tanaka H., Shindo M., Suzuki M. Dietary red pepper ingestion increases carbohydrate oxidation at rest and during exercise in runners. Med. Sci. Sports Exerc. 1997, 29:355-361.
16. Monsereenusorn Y., Kongsamut S., Pezalla P.D. Capsaicin-a literature survey. Crit. Rev. Toxicol. 1982, 10:321-339.
17. Neuvonen P.J. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr. Opin. Investig. Drugs 2010, 11:323-332.
18. Neuvonen P.J., Niemi M., Backman J.T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 2006, 80:565-581.
19. Pawłowska M., Augustin E. Expression systems of cytochrome P450 proteins in studies of drug metabolism in vitro. Postepy Hig. Med. Dosw. 2011, 65:367-376.
20. Perucka I., Oleszek W. Extraction and determination of capsaicinoids in fruit of hot pepper Capsicum annuum L. by spectrophotometry and high-performance liquid chromatography. Food Chem. 2000, 71:287-291.
21. Prueksaritanont T., Gorham L.M., Ma B., Liu L., Yu X., Zhao J.J., Slaughter D.E., Arison B.H., Vyas K.P. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab. Dispos. 1997, 25:1191-1199.
22. Reyes-Escogido M.L., Gonzalez-Mondragon E.G., Vazquez-Tzompantzi E. Chemical and pharmacological aspects of capsaicin. Molecules 2011, 16:1253-1270.
23. Takanohashi T., Isaka M., Ubukata K., Mihara R., Bernard B.K. Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int. J. Toxicol. 2010, 29:22S-26S.
24. Tsukura Y., Mori M., Hirotani Y., Ikeda K., Amano F., Kato R., Ijiri Y., Tanaka K. Effects of capsaicin on cellular damage and monolayer permeability in human intestinal Caco-2 cells. Biol. Pharm. Bull. 2007, 30:1982-1986.
25. Vickers S., Duncan C.A., Vyas K.P., Kari P.H., Arison B., Prakash S.R., Ramjit H.G., Pitzenberger S.M., Stokker G., Duggan D.E. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab. Dispos. 1990, 18:476-483.
26. Wang D., Guo Y., Wrighton S.A., Cooke G.E., Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 2011, 11:274-286.
27. Yuan R., Madani S., Wei X.X., Reynolds K., Huang S.M. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab. Dispos. 2002, 30:1311-1319.
28. Zhang J., Rodila R., Gage E., Hautman M., Fan L., King L.L., Wu H., El-Shourbagy T.A. High-throughput salting-out assisted liquid/liquid extraction with acetonitrile for the simultaneous determination of simvastatin and simvastatin acid in human plasma with liquid chromatography. Anal. Chim. Acta 2010, 661:167-172.
29. Zhang Z., Bu H., Gao Z., Huang Y., Gao F., Li Y. The characteristics and mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats. Int. J. Pharm. 2010, 394:147-153.
30. Zhou S., Koh H.L., Gao Y., Gong Z.Y., Lee E.J. Herbal bioactivation: the good, the bad and the ugly. Life Sci. 2004, 74:935-968.
31. Zhou S.F., Xue C.C., Yu X.Q., Wang G. Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. Curr. Drug Metab. 2007, 8:526-553.